FDA Clears AI Coronary Inflammation Tool; Hofstra Sued Over Bar-Exam Cardiac Arrest

A Bar-Exam Cardiac Arrest Lawsuit and an FDA First for Cardiac Imaging

The week's cardiology headlines are led by a legal dispute over emergency care and a regulatory milestone for artificial intelligence in cardiac imaging. A woman who suffered a cardiac arrest while taking the New York State bar exam is suing Hofstra University, the test site, alleging that staff were slow to provide CPR or use an automated external defibrillator and that fellow test-takers who tried to summon help were discouraged from intervening. News12 reported the suit; the allegations have not been tested in court.

In the device industry, Caristo Diagnostics said its CaRi-Heart software received FDA de novo authorization to quantify coronary inflammation from routine coronary CT angiograms. The de novo pathway is used when no comparable device has been cleared before, which makes the decision a first for this class of AI-based analysis.

The rest of the roundup is a run of study news. The American Society of Echocardiography issued a guideline urging support to minimize long-term work-related musculoskeletal disorders among cardiac sonographers, while Chicago mayoral candidate and cardiologist Lisa Nee discussed her platform on PBS. Clinical research published this week found that multivariable models still fall short in predicting extracranial bleeding from oral anticoagulants (Circulation); that catheter ablation for atrial fibrillation showed no short-term cognitive harm (JAMA Network Open); that prophylactic micro-axial flow pump support was noninferior to veno-arterial extracorporeal membrane oxygenation in high-risk PCI for patients with severely reduced ejection fraction (European Heart Journal); and that longer inflation times for coronary drug-coated balloons were tied to better outcomes in a registry study (Journal of the American Heart Association).

Also out this week: a JAMA Cardiology prospective cohort suggesting mitral regurgitation surgery may offset the mortality risk of a large effective regurgitant orifice area in asymptomatic patients; The Lancet's MIST trial supporting minimally invasive cardiac surgery over standard sternotomy for coronary artery bypass grafting; and a multi-country Journal of the American College of Cardiology study linking heat waves and landscape fire smoke to synergistic cardiovascular hazards.

CaRi-Heart's New Regulatory Class, the MIST Result and Sonographer Strain

CaRi-Heart's De Novo Clearance Opens a New Regulatory Class

The de novo designation matters commercially as much as clinically. Because no predicate device existed, Caristo's clearance establishes the regulatory template for AI-quantified coronary inflammation from routine CTAs — an output that can be produced from imaging already being performed, rather than requiring new scans. That lowers the barrier to adoption in principle, but the practical question is now reimbursement: whether payers will cover the added analysis, and how quickly, will determine whether the clearance translates into revenue. This is interpretation; the digest confirms the authorization but not the company's coverage status.

The MIST Trial, DCB Inflation Times and What They Shift in Practice

Two results speak directly to how procedures are done. The Lancet's MIST trial adds randomized evidence that minimally invasive cardiac surgery can stand in for standard sternotomy in CABG, which may nudge referral patterns and device adoption as guidelines are revisited — although any change will depend on individual centers' surgical experience. The JAHA registry finding on drug-coated balloons is different in kind: longer inflation times cost nothing and require no new hardware, making it a technique adjustment operators can adopt immediately. Neither result is practice-changing on its own, but together they show the field churning toward less invasive approaches.

The Sonographer Guideline Points to a Workforce and Cost Problem

The American Society of Echocardiography's guideline is framed as occupational health, but it reads like a workforce story. Cardiac sonographers perform repetitive, physically demanding scanning, and musculoskeletal disorders are a known driver of pain and attrition in the role. By publishing a formal support guideline, the ASE is signaling that employers, not just individual sonographers, bear responsibility for ergonomics, workloads and equipment. For hospital administrators, that is a retention and labor-cost issue in a specialty already facing staffing pressure — an inference, since the digest itself does not quantify shortages.

Heat, Wildfire Smoke and a Liability Case

The multi-country JACC finding that heat waves and landscape fire smoke act synergistically on cardiovascular health has implications beyond the clinic: health systems, insurers and public-health agencies that model risk from single exposures may be understating hazard when both occur together. Separately, the Hofstra lawsuit is a reminder that emergency-response failures are a legal and reputational risk for any venue that hosts large events — the allegations remain unproven, but the case will put CPR and AED protocols at testing sites under scrutiny.

What Cardiologists, Hospitals and Test Venues Should Take From This Week

This is a digest week, so the practical takeaways vary by audience:

• Hospital administrators and cardiology practices: use the new ASE guideline as a checklist for sonographer ergonomics, workloads and equipment — musculoskeletal injury prevention is a retention and cost issue, not just an occupational-health formality.
• Interventional cardiology teams: the JAHA registry supports longer drug-coated balloon inflation times as a no-cost technique change; review local balloon-inflation protocols against the published data.
• Cardiac surgery programs evaluating CABG approaches: weigh the MIST trial's support for minimally invasive surgery against institutional experience before shifting case selection.
• Law schools and professional exam providers: the Hofstra suit, whatever its outcome, is a prompt to verify CPR/AED equipment, staff training and bystander-intervention policies at large test venues.
• Imaging-AI vendors and cardiology administrators: track CaRi-Heart's coverage and adoption — the de novo clearance likely sets the template for how AI-driven coronary inflammation analysis is regulated and reimbursed.